Enveric Biosciences 株価情報 (NASDAQ: ENVB)

最新ニュース Enveric Biosciences (NASDAQ:ENVB) 株価情報

Enveric Biosciences

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.

Enveric Biosciences Inc

WIIM

PLBY

PLBY Group shares are trading higher after the company announced it will convert 7,000 Series B shares into 3,784,688 shares of Class A common stock.

RBC Capital analyst Paul Treiber maintains Celestica (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CLS#TSX">CLS</a>) with a Outperform and raises the price target from C$115 to C$140.

News

Price Target

Analyst Ratings

TSX:CLS

RBC Capital Maintains Outperform on Celestica, Raises Price Target to C$140

Oppenheimer analyst Noah Kaye maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Outperform and raises the price target from $231 to $237.

Oppenheimer Maintains Outperform on Waste Management, Raises Price Target to $237

JP Morgan analyst Anthony Elian maintains Flagstar Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) with a Neutral and raises the price target from $11 to $12.5.

JP Morgan Maintains Neutral on Flagstar Financial, Raises Price Target to $12.5

RBC Capital analyst Paul Treiber maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Outperform and raises the price target from $115 to $140.

RBC Capital Maintains Outperform on Celestica, Raises Price Target to $140

Oppenheimer analyst Rayna Kumar maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Outperform and raises the price target from $375 to $390.

Oppenheimer Maintains Outperform on Visa, Raises Price Target to $390

JP Morgan analyst Stephen Tusa maintains Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) with a Overweight and raises the price target from $208 to $230.

JP Morgan Maintains Overweight on Dover, Raises Price Target to $230

Oppenheimer analyst Timothy Horan maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Outperform and raises the price target from $250 to $275.

TMUS

Oppenheimer Maintains Outperform on T-Mobile US, Raises Price Target to $275

Phillips 66 Says Trump Tariffs Could Lead To Production Cuts In Us Midwest, Rocky Mountain Region; Closure Of Los Angeles-area Oil Refinery Will Have Material Impact On Cost Structure

JP Morgan analyst Brian Essex maintains Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Neutral and raises the price target from $207 to $221.

CHKP

JP Morgan Maintains Neutral on Check Point Software, Raises Price Target to $221

Oppenheimer analyst Christopher Glynn maintains Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) with a Outperform and raises the price target from $630 to $640.

Oppenheimer Maintains Outperform on Roper Techs, Raises Price Target to $640

POET Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) shares are trading higher on Friday after the company announced it signed an agreement to develop a novel optical engine for a global <a href="https://www.benzinga.com//node/43381079">capital markets firm</a>.
What To Know: The firm plans to use the optical engine for high-frequency securities trading. High-frequency trading involves automated systems that use powerful computers to execute a large volume of trades in fractions of a second.
The development of the optical engine will be carried out in multiple phases, with the goal of increasing speed and reducing latency in the current transceiver solutions used in high-frequency securities trading operations.
Phase one will begin immediately, with POET focused on designing prototypes of POET Optical Interposer-based transceiver engines built to meet the customer's specifications. Subsequent phases will involve the creation of additional prototypes and, if successful, the production of optical engines customized to meet the financial sector&#8217;s needs.
&#8220;We are delighted to have embarked on this ambitious project with a global leader in HFT,&#8221; commented Raju Kankipati, Chief Revenue Officer of POET. &#8220;This project generates revenue for POET this year and demonstrates the versatility of the POET Optical Interposer and the entry into a new, related market space by the Company.&#8221;
Related Link: <a href="https://www.benzinga.com/news/25/01/43395171/walmart-canada-to-invest-about-3-8-billion-over-five-years">Walmart Canada To Invest About $3.8 Billion Over Five Years</a>
POET Price Action: At the time of publication, POET stock is trading 6.92% higher at $4.983, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: This illustration was generated using artificial intelligence via Midjourney.

Movers

POET

What's Going On With POET Technologies Stock Friday?

Goldman Sachs analyst Neil Mehta expressed views on the oil giant Chevron Corp&#8216;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) fourth-quarter earnings reported today. Mehta is Buy-rated on CVX, <a target="_blank" href="https://www.benzinga.com/quote/cvx/analyst-ratings" rel="noreferrer noopener">with a price forecast of $182.</a>
The company reported revenues&nbsp;and other income of&nbsp;$52.23 billion,&nbsp;beating <a target="_blank" href="https://www.benzinga.com/25/01/43382627/chevron-falls-as-q4-profits-decline-amid-lower-oil-output-dividend-hike-offers-silver-lining" rel="noreferrer noopener">the consensus of&nbsp;$46.75 billion</a>.&nbsp;
Adjusted net earnings were&nbsp;$3.63 billion, with adjusted EPS at&nbsp;$2.06&nbsp;(down from&nbsp;$3.45&nbsp;a year ago) in the quarter,<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener"> missing the consensus of&nbsp;$2.11.</a>
Also, the company increased its quarterly dividend by 5% to $1.71 per share.
Mehta states that the company&#8217;s fourth-quarter adjusted EPS was below the GS estimate of $2.11, while production volumes of 3,349 MBOE/d were largely in line with the GS estimates.
The analyst writes that the company&#8217;s guidance for over $10 billion in free cash flow growth by 2026 exceeds their forecast of $9 billion.
Mehta says that he expects the earnings call to focus on progress at TCO following the first oil production announcement, the production outlook in the Permian, updates on the Hess acquisition, and progress on cost reduction initiatives.
Investors can gain exposure to CVX via&nbsp;EA Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and&nbsp;SPDR Select Sector Fund – Energy Select Sector (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Price Action: CVX shares are down 3.7% at $150.54 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43389620" target="_blank" rel="noreferrer noopener">Exxon Mobil Q4 Earnings: Mixed Results, But CEO Promises &#8216;Profitable Growth Well Into the Future&#8217;</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Earnings

Equities

Large Cap

Reiteration

Trading Ideas

DRLL

Chevron's Free Cash Flow Outlook Tops Estimates—Goldman Sachs Sees Upside

Oppenheimer analyst Tyler Batory maintains PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Outperform and lowers the price target from $165 to $150.

Oppenheimer Maintains Outperform on PulteGroup, Lowers Price Target to $150

Oppenheimer analyst Rick Schafer maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Outperform and lowers the price target from $900 to $800.

MPWR

Oppenheimer Maintains Outperform on Monolithic Power Systems, Lowers Price Target to $800

RBC Capital analyst Walter Spracklin maintains Canadian National Railway (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNR#TSX">CNR</a>) with a Outperform and lowers the price target from C$174 to C$171.

TSX:CNR

RBC Capital Maintains Outperform on Canadian National Railway, Lowers Price Target to C$171

Oppenheimer analyst Bryan Blair reiterates Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) with a Outperform and raises the price target from $220 to $225.

Oppenheimer Reiterates Outperform on Dover, Raises Price Target to $225

JP Morgan analyst Samik Chatterjee maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Neutral and raises the price target from $38 to $45.

CALX

JP Morgan Maintains Neutral on Calix, Raises Price Target to $45

Alcoa's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) short percent of float has risen 10.32% since its last report. The company recently reported that it has 9.09 million shares sold short, which is 4.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alcoa Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738345524_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alcoa has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alcoa's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alcoa's peer group average for short interest as a percentage of float is 3.83%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Alcoa's Recent Short Interest

AptarGroup's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>) short percent of float has fallen 3.74% since its last report. The company recently reported that it has 606 thousand shares sold short, which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.14 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AptarGroup Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738345518_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AptarGroup has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AptarGroup's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AptarGroup's peer group average for short interest as a percentage of float is 4.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About AptarGroup?

Enveric Biosciences (ENVB) announced that the United States Patent and Trademark Office USPTO has issued two U.S. Patents, Nos. 12,133,856 the ‘856...

USPTO issues 2 patents for Enveric supporting EVM301 & EVM201 series compounds

Enveric Biosciences ( ($ENVB) ) just unveiled an announcement. Enveric Biosciences, Inc. has announced that it will release an Investor Presentatio...

Enveric Biosciences to Release Investor Presentation

Psychedelic drug developer Lykos could get lifeline from former Tesla board member

17:11 EST Enveric Biosciences (ENVB) files to sell common stock, warrants, no amount given Published first on TheFly – the ultimate source for real...

Enveric Biosciences files to sell common stock, warrants, no amount given

Enveric Biosciences announces offering of common stock and warrants

19:50 EST Enveric Biosciences (ENVB) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving brea...

Enveric Biosciences trading halted, news pending

The company states: Enveric Biosciences (ENVB) announced that it has received a Notice of Allowance from the United States Patent and Trademark Off...

Enveric Biosciences gets Notice of Allowance for EB-003 from USPTO

H.C. Wainwright is acting as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-movi...

Enveric Biosciences 1.67M share Spot Secondary priced at $3.00

Enveric Biosciences stock plummets after pricing $5M capital raise

ATAI

ATNF

CMND

CMPS

CYBN

DRUG

ENVB

GHRS

MNMD

SPRC

Doctor,Hand,Holding,A,Holographic,Of,Human,Brain,In,Healthcare

Biotech

Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit

Press Releases

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025"

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Avenue Therapeutics

China Pharma Holding

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Universe Pharmaceuticals Inc - Ordinary Shares

Comments

Enveric Biosciences

ニュース

最新ニュース Enveric Biosciences (NASDAQ:ENVB) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル